Bloomberg Law
Free Newsletter Sign Up
Bloomberg Law
Advanced Search Go
Free Newsletter Sign Up

FDA Approves Bristol’s Opdivo With Chemotherapy for Lung Cancer

March 4, 2022, 10:49 PM

FDA approves Opdivo (nivolumab) with chemotherapy as neoadjuvant treatment for certain adults with resectable non-small cell lung cancer, Bristol Myers Squibb says.

  • Approval marks the first-and-only immunotherapy-based treatment for use before surgery for non-small cell lung cancer


  • Bristol-Myers Squibb Co. fell 0.2% in postmarket trading to $69.25 as of 5:45 p.m. New York time
    • The average 12-month price target of $72.90 is 5.3% above the current price
    • 15 buys, 9 holds, 0 sells

To view the source of this information, click here

To contact the reporter on this story:
Jim Silver in New York at

To contact the ...